A new study, presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11–14 May) found that a once-weekly dose of tirzepatide can lead to significant and consistent weight loss ...

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

A new once-daily pill may raise the bar for weight loss meds. Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight ...

Learn why experts advise against stopping and restarting GLP-1 drugs, the health risks of weight yo-yoing, and how to manage long-term weight loss safely.

While GLP-1 drugs can be effective for weight loss, they are not necessarily a permanent solution. Therefore, the duration of treatment can vary.

Here’s something worth knowing if you’ve ever logged miles on a treadmill and wondered why the scale isn’t moving: you’re not doing it wrong. The relationship between exercise and weight loss is a ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...

Eli Lilly warns some Medicare plans may exceed the $50 monthly cap for weight‑loss drugs under a new CMS model.

Influencer Kriti Rao's weight loss journey was a combination of better dietary choices and rigorous strength training ...

According to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes. The findings ...